Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
NCT07030517Phase 4Active, not recruiting
- Sponsor
- Johnson & Johnson
- Start
- May 2025
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
A Phase 4 trial of teclistamab in multiple myeloma (MM), sponsored by Johnson & Johnson. Started May 2025; status: active, not recruiting.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07030517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07030517.